- Home
- CVM vs NRXP Comparison
CVM vs NRXP Comparison
Compare CVM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- NRXP
- Stock Information
- Founded
- CVM 1983
- NRXP 2015
- Country
- CVM United States
- NRXP United States
- Employees
- CVM N/A
- NRXP N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- NRXP Health Care
- Exchange
- CVM Nasdaq
- NRXP Nasdaq
- Market Cap
- CVM 63.3M
- NRXP 58.5M
- IPO Year
- CVM 1987
- NRXP N/A
- Fundamental
- Price
- CVM $10.24
- NRXP $3.64
- Analyst Decision
- CVM
- NRXP Strong Buy
- Analyst Count
- CVM 0
- NRXP 5
- Target Price
- CVM N/A
- NRXP $31.40
- AVG Volume (30 Days)
- CVM 138.3K
- NRXP 421.9K
- Earning Date
- CVM 08-14-2025
- NRXP 11-13-2025
- Dividend Yield
- CVM N/A
- NRXP N/A
- EPS Growth
- CVM N/A
- NRXP N/A
- EPS
- CVM N/A
- NRXP N/A
- Revenue
- CVM N/A
- NRXP N/A
- Revenue This Year
- CVM N/A
- NRXP N/A
- Revenue Next Year
- CVM N/A
- NRXP $395.09
- P/E Ratio
- CVM N/A
- NRXP N/A
- Revenue Growth
- CVM N/A
- NRXP N/A
- 52 Week Low
- CVM $1.98
- NRXP $1.10
- 52 Week High
- CVM $32.70
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CVM 56.70
- NRXP 72.98
- Support Level
- CVM $8.69
- NRXP $3.19
- Resistance Level
- CVM $10.83
- NRXP $3.48
- Average True Range (ATR)
- CVM 0.61
- NRXP 0.21
- MACD
- CVM 0.05
- NRXP 0.05
- Stochastic Oscillator
- CVM 76.99
- NRXP 80.10
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.